Latest Clinical News

New Breakthrough May Advance Triple Negative Breast Cancer Treatment (05-30-2016)

By Helen Young Scientists at The Scripps Research Institute have developed a new drug candidate that lowers the growth rate of tumor cells in animal models1 in one of the most difficult cancers to battle: triple negative breast cancer. This is the first... Continue Reading

New Treatment May Reduce Precancerous Polyps in Both Large and Small Intestine in Hereditary Cancer Patients (05-26-2016)

A new study published in the Journal of the American Medical Association (JAMA), has reported a new prevention treatment for individuals at high risk of developing colon cancer due to the APC (adenomatous polyposis coli) gene. Inheriting a mutation in... Continue Reading

More Evidence that PD-1 Inhibitors Improve Survival in Head and Neck Cancer (05-25-2016)

Results from a recent large trial indicate that treatment with the immunotherapy agent Opdivo® (nivolumab) nearly doubles the survival rate at one year in patients with advanced head and neck squamous cell carcinoma. These results prompted the United... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (05-25-2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Lenvima® Approved for Kidney Cancer (05-24-2016)

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic... Continue Reading

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma (05-23-2016)

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an extremely aggressive form of brain cancer, with few... Continue Reading

Addition of Radiation Improves Survival in High-Risk Prostate Cancer (05-18-2016)

The addition of radiation therapy to androgen-deprivation therapy among men with prostate cancer who are at a high risk of a cancer recurrence significantly improves long-term survival. These results were recently published in the journal of European... Continue Reading

Chemotherapy After Prostatectomy Delays Cancer Progression in High-Risk Prostate Cancers (05-17-2016)

The use of chemotherapy following a radical prostatectomy delays the time to cancer progression among men with prostate cancer who are at a high risk of developing a recurrence.  These results were recently presented at the 2016 Annual Scientific Meeting... Continue Reading

Hydrocortisone Significantly Improves Neuropsychological Issues in Some Children with Leukemia (05-16-2016)

The use of physiologic doses of hydrocortisone appears to significantly improve neuropsychological issues caused by treatment including dexamethasone among children with acute lymphoblastic leukemia. These results were published as an early release article... Continue Reading

Avastin®/Camptosar® Improves Outcomes Compared with Temodar® in Glioblastoma (05-12-2016)

The treatment combination consisting of Avastin (bevacizumab) plus Camptosar (irinotecan) improves time to cancer progression compared to treatment with Temodar (temozolomide) in patients with newly diagnosed glioblastoma. These results were recently... Continue Reading

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer (05-11-2016)

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently... Continue Reading

Cabometyx® Approved for Kidney Cancer (05-10-2016)

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already... Continue Reading

Next Page »